TARSUS PHARMACEUTICALS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 36.85 USD | +6.41% |
|
+15.01% | +81.98% |
| 24/04 | BioPharma Credit, Unit to Loan up to $100 Million Each to US-based Tarsus Pharmaceuticals | MT |
| 24/04 | BioPharma Credit to loan USD100 million to Tarsus Pharmaceuticals | AN |
Chart calendar Tarsus Pharmaceuticals, Inc.
c318d437e6b9442f.73Odsyr74cJ_llQ38Yr8GEdKlANtF95RDd7w1oe8hKw.oQL78h_WrJIW2A1Om72-bn54oVEYWrkkd--pgeiF8uOOAt__ZrPW8k_mOw~53960c859e368bc072ee0323c15870ac
Upcoming events on Tarsus Pharmaceuticals, Inc.
Past events on Tarsus Pharmaceuticals, Inc.
| 13/03/2024 07:00 pm | Guggenheim Healthy Altitudes Summit - Fireside Chat |
| 13/03/2024 | Jefferies Biotech on the Bay Summit |
| 13/03/2024 12:35 am | Barclays Global Healthcare Conference - Fireside Chat |
| 27/02/2024 06:30 pm | Q4 2023 Earnings Call |
| 27/02/2024 04:30 pm | Q4 2023 Earnings Release |
| 08/02/2024 11:30 pm | Guggenheim Healthcare Talks Biotechnology Conference |
| 10/11/2023 03:00 am | Q3 2023 Earnings Call |
| 10/11/2023 02:35 am | Q3 2023 Earnings Release |
| 12/09/2023 10:00 pm | Morgan Stanley Global Healthcare Conference |
| 11/09/2023 10:00 pm | H.C. Wainwright Global Investment Conference |
| 11/08/2023 01:35 am | Q2 2023 Earnings Release |
| 25/07/2023 06:00 pm | XDEMVY™ Phase 2a Trial Results Call |
| 22/06/2023 09:30 pm | Annual General Meeting |
| 15/06/2023 09:00 pm | Business Update Call |
| 08/06/2023 12:00 am | Jefferies Global Healthcare Conference - Fireside Chat |
| 10/05/2023 | Bank of America Healthcare Conference |
| 10/05/2023 01:35 am | Q1 2023 Earnings Release |
| 16/03/2023 01:35 am | Barclays Global Healthcare Conference |
| 15/03/2023 08:00 pm | Guggenheim Health Altitudes Summit |
| 14/03/2023 01:35 am | Q4 2022 Earnings Release |
Annual results
| Fiscal Period | December | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|
|
Net sales Million USD | Released Forecast Spread | 0,00 0,00 - | 57,0 49,1 16.22% | 25,8 25,9 -0.17% | 17,4 9,70 79.91% | 103 |
|
EBITDA Million USD | Released Forecast Spread | -26,9 -28,5 5.55% | -11,8 -15,4 23.32% | -62,4 -62,5 0.21% | -142 -138 -3.02% | -132 |
|
EBIT Million USD | Released Forecast Spread | -27,0 -28,3 4.68% | -12,2 -13,6 10.54% | -62,7 -57,0 -9.93% | -143 -144 0.6% | -150 |
|
Earnings before Tax (EBT) Million USD | Released Forecast Spread | -26,8 -27,9 4.04% | -13,8 -14,6 5.78% | -62,1 -55,1 -12.75% | -136 -137 0.83% | -143 |
|
Net income Million USD | Released Forecast Spread | -26,8 -28,1 4.53% | -13,8 -14,9 7.06% | -62,1 -57,9 -7.22% | -136 -137 0.96% | -145 |
|
EPS USD | Released Forecast Spread | -4,32 -2,27 -90.14% | -0,67 -0,57 -16.96% | -2,52 -2,36 -6.78% | -4,62 -4,79 3.52% | -4,22 |
| Announcement Date | 31/03/21 | 14/03/22 | 13/03/23 | 27/02/24 | - |
Quarterly results
| Fiscal Period | December | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Net sales Million USD | Released Forecast Spread | 0,34 4,87 -93.05% | 0,54 2,20 -75.5% | 15,3 11,3 35.8% | 0,00 3,50 - | 10,0 10,0 0% | 2,50 3,33 -25% | 0,00 0,00 - | 1,87 0,36 418.28% | 13,1 5,92 120.73% | 17,9 | 22,8 | 27,4 | 33,8 |
|
EBITDA Million USD | Released Forecast Spread | -14,4 -17,0 15.25% | -19,5 -23,0 15.3% | -5,13 -25,4 79.8% | -22,8 -23,4 2.51% | -15,0 -16,0 6.48% | -24,8 -22,0 -12.95% | -32,6 | -44,1 -36,1 -22.13% | |||||
|
EBIT Million USD | Released Forecast Spread | -14,4 -15,5 6.8% | -19,5 -22,0 11.46% | -5,22 -18,3 71.51% | -22,9 -25,8 11.38% | -15,1 -18,1 16.96% | -25,0 -23,6 -5.56% | -32,8 -29,4 -11.46% | -40,9 -41,9 2.38% | -44,5 -44,9 1.11% | -40,8 | -38,9 | -36,2 | -33,3 |
|
Earnings before Tax (EBT) Million USD | Released Forecast Spread | -14,8 -15,8 6.08% | -20,2 -24,5 17.55% | -5,74 -21,5 73.25% | -22,5 -28,1 19.9% | -13,6 -18,3 25.51% | -23,4 -22,9 -2.14% | -31,4 -29,1 -7.9% | -39,1 -41,9 6.62% | -41,9 -45,4 7.74% | -41,9 | -39,2 | -38,0 | -36,2 |
|
Net income Million USD | Released Forecast Spread | -14,9 -15,4 3.8% | -20,2 -22,2 8.8% | -5,74 -18,5 68.88% | -22,5 -26,0 13.33% | -13,6 -18,1 25.05% | -23,4 -23,5 0.5% | -31,4 -28,6 -9.9% | -39,1 -41,1 4.66% | -41,9 -43,7 4.08% | -39,2 | -37,9 | -35,8 | -32,9 |
|
EPS USD | Released Forecast Spread | -0,72 -0,75 3.57% | -0,98 -0,92 -6.72% | -0,24 -0,72 66.57% | -0,84 -0,97 13.7% | -0,49 -0,69 28.99% | -0,88 -0,95 6.88% | -1,17 -1,08 -8.5% | -1,28 -1,39 7.78% | -1,31 -1,32 0.76% | -1,19 | -1,11 | -1,03 | -0,94 |
| Announcement Date | 14/03/22 | 10/05/22 | 11/08/22 | 09/11/22 | 13/03/23 | 09/05/23 | 10/08/23 | 09/11/23 | 27/02/24 | - | - | - | - |
More events
Past sector events for Tarsus Pharmaceuticals, Inc.
| 03/05/2024 04:37 pm | AARTI DRUGS LIMITED: Q4 2024 Earnings Release |
| 03/05/2024 03:30 pm | AMNEAL PHARMACEUTICALS, INC.: Q1 2024 Earnings Release |
| 03/05/2024 | SCINOPHARM TAIWAN, LTD.: Q1 2024 Earnings Release (Projected) |
| 03/05/2024 | DEVA HOLDING: Q1 2024 Earnings Release (Projected) |
| 03/05/2024 01:31 am | AMGEN INC.: Q1 2024 Earnings Release |
| 02/05/2024 11:13 pm | ALK-ABELLÓ A/S: Q1 2024 Earnings Release |
| 02/05/2024 05:00 pm | ORGANON & CO.: Q1 2024 Earnings Release |
| 02/05/2024 04:30 pm | BAUSCH HEALTH COMPANIES INC.: Q1 2024 Earnings Release |
| 02/05/2024 11:00 am | NOVO NORDISK A/S: Q1 2024 Earnings Release |
| 02/05/2024 | GC BIOPHARMA CORP.: Q1 2024 Earnings Release |
Net sales - Quarter - Rate of surprise
Quarterly earnings - Rate of surprise
Net sales - Annual - Rate of surprise
Annual profits - Rate of surprise
- Stock Market
- Equities
- TARS Stock
- Calendar Tarsus Pharmaceuticals, Inc.
